Encorafenib

Placeholder slot

(EN-kor-A-feh-nib)

This page contains brief information about encorafenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Braftovi

FDA Approved

Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Encorafenib is approved to be used with other drugs to treat patients whose cancer has a certain mutation in the BRAF gene, including:

Colorectal cancer that has spread to other parts of the body. It is used:
- with cetuximab in adults who have received previous treatment
- with cetuximab and mFOLFOX-6
Melanoma. It is used with binimetinib in patients whose cancer cannot be removed by surgery or has spread to other parts of the body.
Non-small cell lung cancer. It is used with binimetinib in adults whose cancer has spread to other parts of the body.

Encorafenib is also being studied in the treatment of other types of cancer.

More About Encorafenib

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Encorafenib - A lay language summary of important information about this drug.

Research Results and Related Resources

Androgen Receptor May Explain Sex Differences in Melanoma Treatment Response

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Encorafenib - Check for trials from NCI's list of cancer clinical trials now accepting patients.